BUPIVACAINE HYDROCHLORIDE INJECTION, USP SOLUTION

দেশ: কানাডা

ভাষা: ইংরেজি

সূত্র: Health Canada

সক্রিয় উপাদান:

BUPIVACAINE HYDROCHLORIDE

থেকে পাওয়া:

STERIMAX INC

এটিসি কোড:

N01BB01

INN (আন্তর্জাতিক নাম):

BUPIVACAINE

ডোজ:

5MG

ফার্মাসিউটিকাল ফর্ম:

SOLUTION

রচনা:

BUPIVACAINE HYDROCHLORIDE 5MG

প্রশাসন রুট:

BLOCK/INFILTRATION

প্যাকেজ ইউনিট:

100

প্রেসক্রিপশন টাইপ:

Ethical

থেরাপিউটিক এলাকা:

LOCAL ANESTHETICS

পণ্য সারাংশ:

Active ingredient group (AIG) number: 0108896004; AHFS:

অনুমোদন অবস্থা:

APPROVED

অনুমোদন তারিখ:

2020-09-11

পণ্য বৈশিষ্ট্য

_ _
_Bupivacaine Hydrochloride Injection, USP Product Monograph Page 1 of
35_
PRODUCT MONOGRAPH
BUPIVACAINE HYDROCHLORIDE INJECTION, USP
2.5 mg/mL,
5 mg
/mL and 7.5 mg/mL Bupivacaine Hydrochloride, USP
Sterile Solution
Local Anesthetic
STERIMAX INC.
Oakville, Ontario
2770 Portland Drive
L6H 6R4
Date of Preparation:
September 8, 2020
Submission Control No: 238228
_ _
_Bupivacaine Hydrochloride Injection, USP Product Monograph Page 2 of
35_
TABLE OF CONTENTS
PART I: HEALTH PROFESSIONAL INFORMATION
......................................................... 3
SUMMARY PRODUCT INFORMATION
.......................................................................
3
INDICATIONS AND CLINICAL USE
.............................................................................
3
CONTRAINDICATIONS
..................................................................................................
4
WARNINGS AND PRECAUTIONS
.................................................................................
4
ADVERSE REACTIONS
.................................................................................................
10
DRUG INTERACTIONS
.................................................................................................
13
DOSAGE AND ADMINISTRATION
.............................................................................
14
OVERDOSAGE
...............................................................................................................
18
ACTION AND CLINICAL PHARMACOLOGY
........................................................... 21
STORAGE AND STABILITY
.........................................................................................
23
SPECIAL HANDLING INSTRUCTIONS
......................................................................
24
DOSAGE FORMS, COMPOSITION AND PACKAGING
............................................ 24
PART II: SCIENTIFIC INFORMATION
..............................................................................
26
PHARMACEUTICAL INFORMATION
.................................